CD47 and familial pancreatic carcinoma: These results show that PI3Kγ inhibitors targeting TAMs may significantly enhance the efficacy of immunotherapy.[38] Targeting macrophage‐derived granulin can be a strategy to improve or restore T‐cell infiltration and cytotoxic function in pancreatic cancer, and as such, this is a potential antitumor therapeutic strategy.[39] Researchers have designed the inhibitor AK750, which not only prevents macrophages from receiving macrophage colony‐stimulating factor (MSF) from cancer cells, but also prevents cancer cells from releasing CD47 protein.